Genesis Mission #1: The Biotech With a "Locked Door" to Cancer

Описание: TITLE: Genesis Mission #1: The Biotech With a "Locked Door" to Cancer

Description: Is Karyopharm Therapeutics (KPTI) setting up for a massive breakout? The "Genesis Mission" has officially begun, and today we are looking at stock #1 of 92 in my master plan.

After an 80% drawdown, KPTI has found a strong floor. Institutional volume is flooding in following a major financing deal that extends their cash runway into 2026. With the Phase 3 SENTRY trial for Myelofibrosis on the horizon, the technicals and fundamentals are finally aligning.

In this video, I break down the "Locked Door" mechanism behind their drug XPOVIO, the critical $8 resistance level we need to watch, and exactly how I plan to manage risk on this trade.

IN THIS VIDEO:

The "Genesis" Pick: Why Karyopharm (KPTI) is the first stock on my radar.

Simple Science: How XPOVIO traps cancer-fighting proteins inside the cell.

The "Smart Money" Signal: Analyzing the massive volume spike from October 8th.

The Trade Plan: My entry strategy, the $8 breakout level, and strictly managing risk to 2%.


⚠️ DISCLAIMER: Not Financial Advice. The content in this video is for entertainment and educational purposes only. I am not a financial advisor. The ideas presented here are my own opinions and personal research. You must do your own due diligence (DYOR) before making any investment decisions. Investing in biotechnology stocks involves extreme risk and volatility.

#KPTI #BiotechStocks #StockMarket #GenesisMission #SwingTrading #PennyStocks #CancerResearch #TechnicalAnalysis #Investing2025